FDA approves First Nasal Spray for Treatment of Anaphylaxis (neffy) epinephrine nasal spray

Neffy (epinephrine 2 mg/dose) is a nasal spray which may be given to treat a severe allergic reaction, including anaphylaxis, in adults and children who weigh 66 pounds (30kg) or more. It is needle-free and considered simple to administer. It is the first non-injectable treatment available for people with life-threatening allergic reactions and gained FDA approval on August 9, 2024.

Neffy works in the same way as epinephrine injections, activating both alpha and beta receptors to constrict blood vessels to maintain blood pressure and heart function, and relax smooth muscles in the airways of the lungs to help relieve shortness of breath and wheezing.

One difference between Neffy and Epipen is that Neffy is a needle-free nasal spray that is sprayed into the nose whereas Epipen is an injection that is given into a big muscle, such as the thigh.

Neffy is manufactured by ARS Pharmaceuticals. Other pharmaceutical companies are also investigating nasal epinephrine. Neffy should be expected to hit the shelves sometime in early October 2024.